Form 4: Adverum Director Sells $2.4M in Stock

Adverum Biotechnologies Director and 10% owner Braden M. Leonard sold 574,886 shares of common stock for approximately $2.4 million across three transactions in early December 2025.

Summary

• Braden M. Leonard, a Director and 10% owner of Adverum Biotechnologies, Inc. (ADVM), reported multiple sales of common stock.
• On December 1, 2025, 300,000 shares were sold at $4.20 per share, totaling $1,260,000.
• On December 2, 2025, 51,961 shares were sold at $4.20 per share, totaling $218,236.20.
• On December 3, 2025, 222,925 shares were sold at $4.17 per share, totaling $929,690.25.
• The total number of shares sold across these three transactions is 574,886, with a total value of approximately $2,407,926.45.
• Following these transactions, Mr. Leonard's indirect beneficial ownership through BML Investment Partners, L.P. decreased from an initial 3,057,526 shares to 2,428,640 shares.
• Mr. Leonard also holds 191,800 shares directly.
• The sales were made pursuant to a Rule 10b5-1 plan.

Sentiment

Score: 3

Explanation: The sentiment is negative due to significant insider selling by a director and 10% owner. While the sales were made under a Rule 10b5-1 plan, the substantial divestment of over $2.4 million can signal a lack of strong conviction or a desire to reduce exposure, which typically weighs on investor confidence.

Negatives

• A Director and 10% owner selling a significant number of shares (574,886 shares) can be interpreted by the market as a lack of confidence in the company's near-term prospects.
• The total value of shares sold, approximately $2.4 million, represents a substantial divestment by a key insider.

Risks

• Negative investor sentiment and potential downward pressure on Adverum Biotechnologies' stock price due to significant insider selling.
• Perception of reduced insider alignment with shareholder interests.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

Insider selling, particularly by a director and significant owner, can be viewed with caution in the biotechnology sector, where company-specific news and clinical trial results often drive stock performance. While sales under a Rule 10b5-1 plan suggest pre-planned divestment rather than an immediate reaction to new information, the sheer volume of shares sold might still raise questions about the insider's long-term conviction, especially given the inherent risks and capital intensity of biotech companies.

Related Party Transactions

• Braden M. Leonard's indirect beneficial ownership is through BML Investment Partners, L.P., where BML Capital Management, LLC serves as the general partner and Mr. Leonard is the managing member. He exercises investment and voting control over these shares, but disclaims beneficial ownership except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders: May interpret the significant insider selling as a negative signal, potentially leading to decreased confidence and downward pressure on the stock price.

Key Dates

Recommendation

While significant insider selling by a director and 10% owner is generally a negative signal, the sales were conducted under a Rule 10b5-1 plan, indicating a pre-scheduled divestment rather than an immediate reaction to new, undisclosed negative information. This mitigates some of the immediate bearish implications. However, the substantial value of shares sold (over $2.4 million) still suggests a reduction in the insider's exposure and conviction. Investors should 'hold' and monitor future company developments and other insider activity, as this filing alone does not provide enough information to warrant a 'sell' recommendation without further analysis of the company's fundamentals and market conditions, but it certainly doesn't support a 'buy'.

Keywords

Adverum Biotechnologies, ADVM, insider selling, Form 4, director stock sale, 10% owner, Braden Leonard, biotechnology stock, Rule 10b5-1